Aujeszky's disease virus eradication campaign successfully heading for last stage in The Netherlands.
The Aujeszky's disease virus (ADV) eradication campaign in The Netherlands is based on compulsory vaccination and certification of ADV-free herds and consists of three stages: reduction of transmission of ADV, tracing and elimination of remaining sources of ADV, and, in the last stage prohibition of vaccination. This paper summarizes the progress made in the first two stages of the eradication. Between 1994-1999, ADV seroprevalence decreased sharply in all four regions in The Netherlands, both in the sow and the finishing pig population. In the sow population, the mean ADV prevalence in the northern, eastern and western regions decreased to less than 0.5% in the first quarter of 1998, and to approximately 1% in the southern region. For the finishing pig population, the mean ADV prevalence decreased to less than 0.6% in all four regions in the first quarter of 1998. The proportion of sow herds that were certified ADV-free increased steadily from approximately 40% in the last quarter of 1996 to 96% in the first quarter of 1999. The proportion of finishing pig herds that were certified ADV-free showed the same spectacular increase as in the sow population: from approximately 14% in the last quarter of 1996 to 90% in the first quarter of 1999. It is anticipated that the last stage of the ADV eradication campaign, stopping vaccination, will be achieved very soon. Monitoring wild boars for ADV between 1994 and 1999 indicated that ADV is uncommon within the wild boar population. Therefore, it seems that ADV infection in the wild boar population is not an important reservoir in The Netherlands.
Elbers
A R
AR
Department of Pig Health, Animal Health Service, Boxtel, The Netherlands.
Braamskamp
J
J
Dekkers
L J
LJ
Voets
R
R
Duinhof
T
T
Hunneman
W A
WA
Stegeman
J A
JA
D000818:Animals; D000829:Animals, Domestic; D000835:Animals, Wild; D000914:Antibodies, Viral / Q000097:blood; D016000:Cluster Analysis; D004197:Disease Reservoirs / Q000662:veterinary; D005062:European Union; D005260:Female; D011558:Herpesvirus 1, Suid / Q000276:immunology*; D009426:Netherlands / Q000453:epidemiology; D011557:Pseudorabies / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D016036:Seroepidemiologic Studies; D013552:Swine; D013553:Swine Diseases / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination / Q000662:veterinary*; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology / Q000592:standards
D000914:Antibodies, Viral; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C089580:glycoprotein E, Suid herpesvirus 1